Literature DB >> 2365005

Long-term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain.

J Harro1, A Lang, E Vasar.   

Abstract

This study examined the effect of chronic diazepam administration on central benzodiazepine and CCK-8 receptor binding in rat brain. After a two-week treatment with diazepam (5 mg/kg per day) tolerance developed towards the sedative but not towards the anxiolytic action of this drug as determined using elevated plus-maze and open field tests. The % entries the rats made onto open arms and % time the rats spent in open arms were markedly decreased 24 h after the last dose of diazepam, probably indicating withdrawal anxiety. There were no changes in [3H]flunitrazepam binding either 30 min or 24 h after the last diazepam dose. However, 30 min after the last diazepam administration the apparent number of sulphated [3H]CCK-8 binding sites was significantly increased in the primary olfactory cortex. Acute diazepam treatment (5 mg/kg) had no influence on [3H]flunitrazepam or sulphated [3H]CCK-8 binding in any brain region studied. Cessation of chronic diazepam treatment was followed after 24 h by an increase in the number of CCK-8 receptors in frontal cortex and hippocampus as compared to the vehicle group. These results demonstrate that certain alterations in CCK-8 receptor characteristics may be important in the anti-anxiety effect, tolerance, and withdrawal reaction reaction after benzodiazepine administration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2365005     DOI: 10.1016/0014-2999(90)90594-v

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988.

Authors:  L Singh; M J Field; C A Vass; J Hughes; G N Woodruff
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

Review 2.  Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.

Authors:  Peter Zwanzger; Rainer Rupprecht
Journal:  J Psychiatry Neurosci       Date:  2005-05       Impact factor: 6.186

3.  The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.

Authors:  P Chopin; M Briley
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Effects of the CCKB antagonist L-365, 260 on benzodiazepine withdrawal-induced hypophagia in rats.

Authors:  A J Goudie; M J Leathley
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

5.  Regional changes in neuropeptide levels after 5,7-dihydroxytryptamine-induced serotonin depletion in the rat brain.

Authors:  Y Kondo; N Ogawa; M Asanuma; H Hirata; K Tanaka; Y Kawada; A Mori
Journal:  J Neural Transm Gen Sect       Date:  1993

6.  Social isolation of rats increases the density of cholecystokinin receptors in the frontal cortex and abolishes the anti-exploratory effect of caerulein.

Authors:  E Vasar; E Peuranen; J Harro; A Lang; L Oreland; P T Männistö
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

7.  Cholecystokinin peptides and receptors in the rat brain during stress.

Authors:  J Harro; C Löfberg; J F Rehfeld; L Oreland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-06       Impact factor: 3.000

8.  Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.

Authors:  H J van Megen; H G Westenberg; J A den Boer; J R Haigh; M Traub
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

9.  Changes in cholecystokinin receptor binding in rat brain after selective damage of locus coeruleus projections by DSP-4 treatment.

Authors:  J Harro; S S Jossan; L Oreland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-10       Impact factor: 3.000

10.  Benzodiazepine/cholecystokinin interactions at functional CCK receptors in rat brain.

Authors:  P R Boden; G N Woodruff
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.